Connect with us

Cannabis News

FDA’s New Hemp CBD Enforcement Move Is Encouraging, But Congress Still Needs To Enact Real Regulations (Op-Ed)

Published

on

“These products have the potential to reshape how Americans approach wellness by providing accessible plant-based alternatives to traditional care, but realizing that potential will require more than discretion.”

By Thomas Winstanley, Edibles.com

For years, the hemp-derived CBD market has operated in a paradox: federally legal, accessible, and increasingly standardized, but without a clear regulatory framework that provides confidence to consumers and stability to businesses. The The latest move by the Food and Drug Administration (FDA) to use enforcement discretion for certain CBD products it is a significant step forward, emphasizing how incomplete and fragile the current system is.

Essentially, the FDA’s position acknowledges that hemp-derived cannabinoids are part of Americans’ daily wellness routine. By announcing its intention to enforce certain provisions of the Federal Food, Drug, and Cosmetic Act against orally administered CBD products, the agency is recognizing a practical way forward that is rooted in a supplemental framework with safety, labeling, and marketing protections.

That matters. For the first time in decades, cannabinoids are being discussed in terms that resemble the Dietary Supplement Health and Education Act of 1994 (DSHEA). The implication is a viable path forward for CBD products, as consumers already engage with wellness through vitamins, nutraceuticals and other over-the-counter formats, with expectations of quality and transparency.

But let’s be clear about what this is and what it isn’t.

This is not absolute regulatory approval. It does not establish CBD as Generally Recognized as Safe (GRAS), and does not create lasting protection for the wider market. Instead, it reflects a selective enforcement policy under narrow conditions. Products must meet supplement-style standards, avoid contamination, be child-resistant, and dispensed in a physician-directed Medicare-affiliated setting. That last point is where the gap is most obvious.

FDA’s position is limited to a very specific use case related to healthcare programs. It does nothing to address the much larger and more dynamic reality of the national consumer market, which includes retail, e-commerce and direct-to-consumer platforms. Here’s where millions of Americans already access CBD and companies have built entire categories without federal oversight.

Industry is no longer a fringe experiment. Since the 2018 Farm Bill, hemp-derived products have grown into a multibillion-dollar industry, expanding access to cannabinoids in ways that state-regulated cannabis markets cannot. In doing so, the category has helped normalize THC and reshape public perception, introducing new consumers and expanding acceptance of plant-based alternatives to wellness.

Consumers are integrating these products into their daily lives. Sleep support, stress management, recovery and general wellness are the core use cases today. From small businesses to national platforms, companies have also invested heavily in building responsible and compliant offerings to meet this demand. However, the rules governing this market remain fragmented and sometimes contradictory.

Federal agencies continue to send mixed signals. States have established a patchwork of consistent standards. Responsible operators such as those investing in testing, labeling and compliance are forced to compete alongside bad actors who exploit regulatory gray areas. The result is a market that works, but not efficiently and certainly not safely at scale. Therefore, the FDA’s move, while encouraging, is not a comprehensive solution.

Selective enforcement is not regulation. It offers temporary flexibility, not long-term certainty. It expresses tolerance, not acceptance. Without action from Congress, the entire category is vulnerable to sudden policy changes that could disrupt supply chains, deter investment and erode consumer confidence.

In fact, recent legislation is in danger of holding the industry back. The narrowing of the federal definition of hemp in the final credit framework introduces new ambiguity around product eligibility, particularly for cannabinoids that fall outside the traditional interpretation.

Without clear federal standards, we risk an outcome worse than the problem policymakers are trying to solve. Rules that are too restrictive or unclear will not remove the application. They will simply redirect you to unregulated or imported products that potentially lack basic safety oversight. That’s a real consumer protection risk.

At the same time, the US must dismantle a largely domestic supply chain as it reaches significant scale, undermining the farmers, manufacturers and retailers who have diligently built this industry. None of this is to dismiss the FDA’s progress.

The agency deserves credit for taking a pragmatic step forward. Its emphasis on pollution-free products, responsible marketing and clear labeling reflects principles that the entire industry should embrace. These are not debatable standards. These are basic expectations. However, they should be applied broadly, not selectively.

FDA’s recent actions and increasing alignment between the executive branch and the legislature indicate the need for a federal framework. It reflects openness to integrating cannabinoids into established regulatory systems. It also reinforces the importance of safety and supervision. What it doesn’t do is solve the problem.

Only Congress can provide the clarity this market demands. A comprehensive federal framework that establishes consistent standards for manufacturing, labeling, distribution, and access is needed. This step is essential to unlocking the full potential of hemp-derived cannabinoids.

This is a significant opportunity. These products have the potential to reshape how Americans approach wellness by providing accessible plant-based alternatives to traditional care, but realizing that potential will require more than discretion. He will ask for a policy. Until then, the FDA’s change is a step in the right direction. It is not the destination.

Thomas Winstanley is Executive Vice President and CEO Edibles.com®an innovative and reliable marketplace for high-quality THC products, offering convenient direct-to-consumer delivery.

user photo Nanny Kimzy.

Marijuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.

Cannabis News

MMJDaily will be back August 10th

Published

on

By


Even the best growers need a dark cycle. MMJDaily is shutting down for the annual two-week summer break. There will be no newsletter in your inbox or new articles on the website for the next two weeks, but we will be back on August 10th. Thank you, as always, for following and supporting our work. Rest…

Continue Reading

Cannabis News

Adding Hemp To Dog Food Improves Digestive Health, New Study Shows

Published

on

By

A new study has found that adding hemp oil or a hemp seed byproduct to dog food can improve digestive health without negatively affecting the overall microbial system.

Research published in the journal Veterinary Sciences suggests that some types of hemp derivatives can be safely included as ingredients in dog food. However, the effects appear to depend in part on whether the cannabis is added as an oil or fiber supplement.

For the study, researchers at Kasetsart University in Thailand divided 24 mixed-breed dogs into three groups: one fed food with an 11 percent concentration of a high-fiber hemp seed byproduct, one received food containing 2 percent hemp seeds, and a third received a control diet without hemp.

The dogs were fed the diets for 90 days. The researchers compared the stool samples before the experiment and after 30 and 90 days. Genetic sequencing was used to track changes in gut bacterial composition and diversity.

Dogs fed hemp seed oil-infused food experienced a greater increase in microbial species richness.

“Hemp seeds modulate the canine microbiome without disrupting the ecological stability of the specific formulation, contributing to beneficial health effects in canine nutrition.”

The diet was also associated with increased levels of “beneficial” bacteria from the Lactobacillaceae family, and the fiber-rich hemp seed byproduct Actinobacteriota.

“Hemp seed derivatives altered the microbial composition by promoting beneficial bacteria that promoted gut health in dogs in a formulation-dependent manner,” the authors wrote, and the results “provide evidence for their inclusion as a functional ingredient in dog food.”

Despite the differences between the diets, 19 key bacterial collections were present throughout to analyze. And by day 90, the microbial composition also seemed to stabilize, indicating that the dietary supplements did not significantly disrupt the dogs’ intestinal systems.

Overall, the findings suggest that hemp seed ingredients can be safely incorporated into dog food while protecting gut health by promoting beneficial bacteria, the study authors said.

This is one of the latest studies on cannabis and its effects on dogs.


It’s Marijuana Time tracking hundreds of cannabis, psychedelic and drug policy bills in state legislatures and Congress this year. Patreon supporters by pledging at least $25/month, you’ll get access to our interactive maps, charts, and audio calendars so you never miss a development.


Learn more about our marijuana bill tracking and become a Patreon supporter to gain access

For example, a systematic review of the scientific literature determined that studies “consistently show” this CBD is a potential “anti-cancer agent” in various types of cancer—and this effect applies to both dogs and humans.

The National Animal Supplement Council (NASC) sponsored a study in 2024 said that CBD is “safe for long-term use” in dogs—This is a significant finding given the emerging research that cannabis can effectively treat anxiety and certain skin conditions in dogs.

Another 2024 case study found this Cannabis appears to be a “viable alternative” treatment option for dogs suffer from a common skin disease, especially if they suffer from the adverse side effects of conventional steroid therapies.

Meanwhile, previous research suggests that Giving dogs a dose of CBD can help reverse the ill effects of accidental THC consumptionaccording to a study by the authors titled “First report of treatment of THC toxicosis in dogs with administration of CBD.”

Another study published in 2024 found that Dogs receiving daily doses of CBD see “significant reductions” in stress and anxiety related to car trips.

Other studies have demonstrated the benefits of CBD, such as the frequency of seizures among dogs receiving the cannabinoid is reduced. Moreover, a study published in 2018 found this dogs with arthritis see improvements with CBD treatment.

As for other animals, it was discovered by the US Department of Agriculture (USDA) in 2013 Cows fed hempseed cake maintain very low concentrations of THC and CBD in their bodies, indicating that meat products from hemp-fed cows are safe for human consumption.

Another federally funded study published in 2022 found this Feeding hemp to cows reduces stress.

It has also been studied by researchers How CBD affects stress and pain in horses.

Marijuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.

Become a patron on Patreon!

Continue Reading

Cannabis News

Ora Pharm affirms uninterrupted access to Helius products

Published

on

By

Ora Pharm has confirmed that New Zealand patients, prescribers and pharmacies continue to have uninterrupted access to Helius Therapeutics products following the successful acquisition of the business and its key assets, directly challenging the misinformation being circulated to patients and prescribers by cannabis importer MW Pharma Limited (trading as NUBU).

Industry monitoring was highlighted on Monday, July 20th, when Helius Therapeutics announced that NZ Grow Co. As he inaugurated Growers Day. The event demonstrated the full operational strength, advanced capabilities and integrated supply chain now fully operational under Ora Pharm’s leadership to support the growth of the NZ sector.

At the event, CEO Zoë Reece addressed concerns stemming from a July 9 industry bulletin distributed by NUBU, which stated that “Helius Therapeutics has ceased production and all products are now discontinued.”

© Ora Pharm

Ora Pharm said the statement was incorrect and had the potential to create unnecessary uncertainty in a highly regulated healthcare sector.

“Inaccurate information about the availability of medicines can cause unnecessary worry for patients, prescribers and pharmacies, interfere with treatment decisions and undermine confidence in the New Zealand cannabis industry.”

Ora Pharm completed the business and acquisition of key assets of Helius Therapeutics on June 18, 2026, resuming manufacturing, packaging and nationwide distribution the following day. All Helius brand formulated products and locally grown products remain approved and available for patient supply.

CEO Zoë Reece said the company’s focus is on ensuring continuity of care while strengthening New Zealand’s medicinal cannabis industry.

“The Helius facility gives New Zealand growers direct access to world-class pharmaceutical drying, extraction and manufacturing capabilities. Combined with NZ Grow Co., we are creating a secure and integrated pathway from cultivation to finished products and international markets. Our focus is on clinical continuity, quality assurance and confidence in patients and prescribing physicians every day.”

© Ora Pharm

The integration of the GMP-certified Auckland manufacturing facility with NZ Grow Co.’s cultivation network creates New Zealand’s largest medicinal cannabis supply chain. This unified network insulates domestic patients from volatile international import dependencies while providing independent local growers with a transparent, high-standard route to export markets.

Ora Pharm remains committed to working collaboratively across the sector to support patient access, strengthen confidence in the New Zealand cannabis industry and continue to invest in New Zealand’s pharmaceutical manufacturing capacity.

For more information:
Ora Pharm
(email protected)
www.orapharm.co.nz

Continue Reading
Advertisement

Trending

Copyright © 2021 The Art of MaryJane Media